This text is a result of machine translation.
Fosun Pharmaceutical: the new tablet production line of the holding subsidiary passed the GMP compliance inspection
Xuelang environment: affected by the epidemic situation, the subsidiary temporarily stopped production and resumed production
China's First Oral COVID-19 Antiviral Medicine in Dispute
An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.
Aug 08, 2022 09:00 AM
Fosun Pharmaceutical: the holding subsidiary started the phase II clinical study on the treatment of fs-1502 for non-small cell lung cancer
On May 11, Ping An of China spent 299 million yuan to buy back 6.6972 million a shares
2022 China AI Health 30 Report
Sichuan Energy Investment Development: RMB 152 million subscription for Principal Guaranteed structured deposit products of Bank of Communications
Jiangsu Province has issued the outline of building a strong province with intellectual property rights, and will be fully built into a strong province with intellectual property rights in 2035
Tesla unveiled a new giant 360mwh Megapack energy storage project
Air China: passenger turnover increased by 1.1% month on month in February
Chengda biology: transfer relevant assets of Benxi human vaccine base to a wholly-owned subsidiary
Baidu responded that it was unable to search "referee document network": caused by misoperation of the technical team
Yingsi intelligence and Fosun Pharmaceutical reached the first milestone of strategic cooperation: nomination and targeting cd47-sirp α Small molecule compounds of signal pathway
Fosun Pharma Net Profit down 45% in Q1 2022 as Value of Financial Assets Slumps
Founded in 1994, Shanghai Fosun Pharma is a global pharmaceutical and health group rooted in China and driven by innovation. Its businesses include pharmaceuticals, medical devices and diagnosis, medical and health services. The group covers the pharmaceutical field through participation in Sinopharm Holdings.
Apr 27, 2022 10:55 PM
Jiuyuan Yinhai: the holding subsidiary has passed the CMMI5 evaluation and certification
Shenghe resources: it plans to acquire 19.9% equity of peak company
China Resources materials: the affiliated company China Resources Assets became the reorganization investor of Chenggao packaging and other four companies
Rongchuang transferred the equity of Wenzhou No. 1 project company, and the transferee was Dexin real estate
WaveFront Ventures: How Can Chinese Companies Win the Global Robotic Race
Mar 24, 2023 02:02 PM
CIRCUE: AI Drives the Revolution of Energy, Leading a Sustainable Future
Mar 23, 2023 12:26 PM
Charging Infrastructure on Government Support: A Brighter Future?
Mar 16, 2023 06:03 PM
Robot Policies in Asia
Mar 10, 2023 10:51 AM